Last reviewed · How we verify
Acetyl Salicylic acid
Acetyl Salicylic Acid, marketed by Kasr El Aini Hospital, is a well-established drug with a key composition patent expiring in 2028. The drug's primary strength lies in its long-standing market presence and recognized efficacy. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Acetyl Salicylic acid |
|---|---|
| Also known as | Aspirin, Primaspan 250 mg tablet |
| Sponsor | Kasr El Aini Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy (PHASE3)
- The Copenhagen Analgesic Study
- Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks (NA)
- Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP) (PHASE2)
- Aggravated Airway Inflammation: Research on Genomics and Optimal Medical Care (AirGOs-medical) (NA)
- Metabolic Effects of Duodenal Jejunal Bypass Liner for Type 2 Diabetes Mellitus
- Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study (NA)
- A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acetyl Salicylic acid CI brief — competitive landscape report
- Acetyl Salicylic acid updates RSS · CI watch RSS
- Kasr El Aini Hospital portfolio CI